Volasertib
Term · Oncology and biomedicine · MLC-T-ONC-017528
A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.
| Identifier | MLC-T-ONC-017528 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | PLK-1 inhibitor BI 6727 |
| Synonyms | Polo-like kinase 1 inhibitor BI 6727 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017528",
"term": "Volasertib",
"field": "Oncology and biomedicine",
"definition": "A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.",
"abbreviation": "PLK-1 inhibitor BI 6727",
"synonyms": [
"Polo-like kinase 1 inhibitor BI 6727"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/volasertib/"
}
Record 17,321 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.